BOSTON–(BUSINESS WIRE)–June 27, 2019 — Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…Original Article
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
